2024
Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samples
2023
The impact of ABO and RhD blood types on Babesia microti infection
Jajosky R, O’Bryan J, Spichler-Moffarah A, Jajosky P, Krause P, Tonnetti L. The impact of ABO and RhD blood types on Babesia microti infection. PLOS Neglected Tropical Diseases 2023, 17: e0011060. PMID: 36696414, PMCID: PMC9901808, DOI: 10.1371/journal.pntd.0011060.Peer-Reviewed Original ResearchConceptsB. microti infectionABO blood typeBabesia microti infectionMicroti infectionBlood donorsBlood typeDisease severityPlasmodium falciparum malaria patientsFalciparum malaria patientsHigher peak parasitemiaRed blood cell antigensType BImpact of ABOBlood cell antigensBlood type BMalaria patientsTransfusion strategyInfected donorsRhD blood typeSevere diseasePeak parasitemiaB antigensCell antigensPossible associationRhD antigen
2022
Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States
Bloch E, Zhu X, Krause P, Patel E, Grabowski M, Goel R, Auwaerter P, Tobian A. Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States. Open Forum Infectious Diseases 2022, 9: ofac597. PMID: 36467296, PMCID: PMC9709699, DOI: 10.1093/ofid/ofac597.Peer-Reviewed Original ResearchNational Inpatient SampleLyme diseaseMale patientsAnnual incidenceHealth burdenLonger hospital stayMean hospital chargesHigher inpatient costsHospital-level variablesStratified systematic random sampleUS Census Bureau dataPerson/yearHospital stayPatient demographicsHospital admissionClinical outcomesHospital chargesInpatient costsInpatient hospitalizationInpatient SampleAdmission costsHospitalizationUS hospitalsDisease severitySystematic random sample
2020
Parasite burden and red blood cell exchange transfusion for babesiosis
O'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. Journal Of Clinical Apheresis 2020, 36: 127-134. PMID: 33179803, PMCID: PMC9517950, DOI: 10.1002/jca.21853.Peer-Reviewed Original ResearchConceptsEnd-organ dysfunctionPeak parasitemia levelsRed blood cell exchange transfusionParasitemia levelsExchange transfusionPeak parasitemiaDisease severityParasite burdenYale-New Haven HospitalBabesia microti parasitemiaHigh-grade parasitemiaRetrospective chart reviewBabesia microti infectionNew Haven HospitalAntimicrobial agentsChart reviewHepatic dysfunctionPatient demographicsClinical statusMedian lengthLaboratory indicatorsMicroti infectionDegree of hemolysisNineteen subjectsDysfunction
2015
Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences
Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences. Trends In Parasitology 2015, 32: 30-42. PMID: 26613664, PMCID: PMC4713283, DOI: 10.1016/j.pt.2015.09.008.Peer-Reviewed Original ResearchConceptsB. microtiDisease severityGreater disease severityEnzootic cycleCoinfected individualsTick-borne pathogenClinical consequencesTherapeutic strategiesLyme diseaseBabesia microtiHost factorsCoinfectionBorrelia burgdorferiB. burgdorferiIxodes ticksMicrotiReservoir hostsSeverityHuman pathogensBurgdorferi
2007
Serum Reactivity against Borrelia burgdorferi OspA in Patients with Rheumatoid Arthritis▿
Hsieh YF, Liu HW, Hsu TC, Wei J, Shih CM, Krause PJ, Tsay GJ. Serum Reactivity against Borrelia burgdorferi OspA in Patients with Rheumatoid Arthritis▿. MSphere 2007, 14: 1437-1441. PMID: 17881508, PMCID: PMC2168181, DOI: 10.1128/cvi.00151-07.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialAntigens, SurfaceArthritis, RheumatoidAutoimmune DiseasesBacterial Outer Membrane ProteinsBacterial VaccinesBlotting, WesternBorrelia burgdorferiEnzyme-Linked Immunosorbent AssayFemaleHumansLipoproteinsLyme DiseaseMaleMiddle AgedRecombinant Fusion ProteinsConceptsRheumatoid arthritis patientsRheumatoid arthritisOspA antigenArthritis patientsAutoimmune diseasesSerum reactivityLyme diseaseDisease Activity ScoreCommon clinical featuresLyme disease patientsSurface protein AArthritis correlatesSynovial histologyOuter surface protein ALyme arthritisActivity scoreClinical featuresDisease patientsSerum concentrationsSimilar pathogenesisHealthy subjectsPatientsArthritisDisease severityDisease